Resolute Integrity US A Postapproval Study of the Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm
Phase of Trial: Phase IV
Latest Information Update: 26 May 2017
At a glance
- Drugs Zotarolimus (Primary)
- Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms RI-US
- Sponsors Medtronic
- 04 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Jan 2015 Planned primary completion date changed from 1 Aug 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 31 May 2013 Planned end date changed from 1 Feb 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov.